Pharmaceutical Benefits [substance] Amendment Determination 2007 (No. )

PB 15 of 2011

National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 2)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Determination under section 85B of the National Health Act 1953.

Dated 18 February 2011

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1 Name of Instrument

(1) This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2011 (No. 2).

(2) This Instrument may also be cited as PB 15 of 2011.

2 Commencement

This Instrument commences on 1 March 2011.

3 Amendment of PB 109 of 2010

Schedule 1 amends PB 109 of 2010.

Schedule 1 Amendments

[1] Schedule 1, entry for Bleomycin

omit:

Injection

Blenoxane

439.63

903.27

[2] Schedule 1, entry for Pindolol

omit:

Tablet 5 mg

Oral

Visken 5

100

4.18

6.42

[3] Schedule 2, entry for Naratriptan

insert after the second paragraph in the column headed “Circumstances”:

Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions are expected to occur with other suitable PBS-listed drugs.

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.